Leuven

• A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Recruiting
  2023-506503-26-00 5 2024-07-31 Polyneuropathy, Inflammatory Demyelinating, Chronic
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 6 2024-07-31 Moderately to Severely Active Crohn’s Disease
• A long-term follow-up study for patients treated with Galapagos CAR T cell therapies Recruiting
  2023-510173-34-00 5 2024-07-26 Relapsed/refractory multiple myeloma
• A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt … Recruiting
  2023-507684-19-00 5 2024-07-24 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
• A study to investigate efficacy, safety, and tolerability of mavorixafor in participants with congenital and acquired primary autoimmune and … Recruiting
  2023-508482-32-00 5 2024-07-22 Neutropenias
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate … Recruiting
  2024-511309-47-00 4 2024-07-17 moderate thrombocytopenia
• Add-on Clioquinol in drug-resistant epilepsy: an exploratory study Recruiting
  2024-511388-27-04 4 2024-07-16 Drug resistant epilepsy
• Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting
  2023-507641-29-00 4 2024-07-15 Locally Advanced or Metastatic Solid Tumors
• A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting
  2022-502629-16-00 5 2024-07-10 Hemolytic Disease of the Fetus and Newborn (HDFN)
• N-PLUS Recruiting
  2022-502559-69-01 4 2024-07-04 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i … Recruiting
  2023-508204-38-00 5 2024-07-02 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT) Recruiting
  2022-500210-26-00 5 2024-06-28 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Personalized medicine for advanced biliary cancer patients Recruiting
  2023-508100-38-00 5 2024-06-24 Advanced Biliary Cancer (ABC)
• A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants … Recruiting
  2022-501697-19-01 5 2024-06-18 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
• Enhancing social attunement in autism via interpersonal sensorimotor synchronization therapy combined with single-dose intranasal oxytocin a … Recruiting
  2023-505253-41-01 5 2024-06-18 Autism Spectrum Disorder (ASD)
• Phase 2, randomised study of Radspherin® in patients with primary advanced epithelial cancer with peritoneal metastasis that are homologous … Recruiting
  2023-508497-28-00 4 2024-06-05 Carcinomatosis of peritoneal cavity
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit … Recruiting
  2022-502404-73-00 4 2024-06-03 Pancreatic ductal adenocarcinoma
• Anti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A Recruiting
  2023-507348-35-00 6 2024-05-30 Risk for Type 1 Diabetes
• An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evalu … Recruiting
  2023-508818-42-00 10 2024-05-21 Generalized Epidermolysis Bullosa Simplex (EBS)
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• Safety, Tolerability, PK, PD, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia Recruiting
  2023-505995-31-00 7 2024-05-03 Glanzmann Thrombasthenia
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• Budesonide as a treatment for inflammation in stomach complaints. Recruiting
  2024-517035-43-00 6 2024-05-01 Functional Dyspepsia
• A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch … Recruiting
  2023-505660-11-00 5 2024-04-24 Cholangiocarcinoma (LTT, 26.0)

Showing 409–432 of 1,135 trials